Clinical experience with Neoral® (cyclosporine for microemulsion) in renal transplantation

B. W. Miller, D. C. Brennan

Research output: Contribution to journalReview articlepeer-review


The microemulsion formulation of cyclosporine (Neoral®) represents a major advance in treatment, improving pharmacokinetics and permitting a more rational strategy for the administration and monitoring of therapy. Neoral consistently increases C(max) and AUC while decreasing T(max). The long-term benefits of this preparation in the rapidly-changing environment of renal transplantation immunosuppression are being studied. Optimal immunosuppressive treatment continues to evolve, with potential future roles for such newer developments as tacrolimus and a less costly genetic form of conventional cyclosporine.

Original languageEnglish (US)
Pages (from-to)73-86
Number of pages14
JournalToday's Therapeutic Trends
Issue number1
StatePublished - 1998
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Clinical experience with Neoral® (cyclosporine for microemulsion) in renal transplantation'. Together they form a unique fingerprint.

Cite this